Skip to main content

. 1966 Oct;105(4):249–256.

Gout and gouty arthritis. Current concepts and management.

PMCID: PMC1516500 PMID: 5976880

Images in this article

Figure 1.
on p.250-1

Figure 2.
on p.250-1

Figure 3.
on p.250-1

Figure 4.
on p.250-1

Figure 5.
on p.250-1

Figure 6.
on p.250-1

Figure 7.
on p.250-1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

BURNS J. J., YU T. F., RITTERBAND A., PEREL J. M., GUTMAN A. B., BRODIE B. B. A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther. 1957 Mar;119(3):418–426. [PubMed] [Google Scholar]
GUTMAN A. B. The search for uricosuric agents suited to the management of tophaceous gout. N Y State J Med. 1963 Feb 15;63:576–585. [PubMed] [Google Scholar]
MCCARTY D. J., HOLLANDER J. L. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961 Mar;54:452–460. doi: 10.7326/0003-4819-54-3-452. [DOI] [PubMed] [Google Scholar]
Rundles R. W., Metz E. N., Silberman H. R. Allopurinol in the treatment of gout. Ann Intern Med. 1966 Feb;64(2):229–258. doi: 10.7326/0003-4819-64-2-229. [DOI] [PubMed] [Google Scholar]
Wyngaarden J. B. Xanthine oxidase inhibitors in the management of gout. Arthritis Rheum. 1965 Oct;8(5):883–890. doi: 10.1002/art.1780080452. [DOI] [PubMed] [Google Scholar]

ACTIONS

PDF (2.0 MB)

RESOURCES